Russia approves trial of AstraZeneca COVID-19 vaccine: registry submitting
Britain's AstraZeneca (AZN.L) has obtained regulatory approval to conduct part of a Phase III trial of its prospective COVID-19 vaccine in Russia, a filing at the Russian registry of clinical trials showed on Friday.
The trial of this AZD1222 vaccine will involve 150 participants and will be handled by four medical facilities in St. Petersburg and Moscow, the submitting, dated Friday, revealed.
Moscow has previously agreed a deal with AstraZeneca to manufacture the prospective vaccine, developed in tandem with Oxford University, at the facilities of Russian firm R-Pharm.
The British drugmaker said in an announcement last week that late-stage trials of its vaccine were continuing in Britain and in Brazil, an early-stage trial was progressing in South Africa, and that further trials were proposed in the U.S., Japan and Russia.
Russia is also developing several possible COVID-19 vaccines domestically, together with late-stage trials of this front-runner candidate, nicknamed'Sputnik-V', set to start next week.
The trial of this AZD1222 vaccine will involve 150 participants and will be handled by four medical facilities in St. Petersburg and Moscow, the submitting, dated Friday, revealed.
Moscow has previously agreed a deal with AstraZeneca to manufacture the prospective vaccine, developed in tandem with Oxford University, at the facilities of Russian firm R-Pharm.
The British drugmaker said in an announcement last week that late-stage trials of its vaccine were continuing in Britain and in Brazil, an early-stage trial was progressing in South Africa, and that further trials were proposed in the U.S., Japan and Russia.
Russia is also developing several possible COVID-19 vaccines domestically, together with late-stage trials of this front-runner candidate, nicknamed'Sputnik-V', set to start next week.
